ABUS·Nasdaq·US
Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on developing therapeutics for chronic hepatitis B and other viral diseases. The company also develops lipid nanoparticle delivery and RNA-targeted technology platforms and derives value from research programs, licensing, and collaborations.
Recent Activity
Updated Oct 3, 2026
–Arbutus Biopharma completed a US$230 million modified "Dutch Auction" tender offer, with approximately 65.7 million shares validly tendered and accepted based on the final results.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.